Pulse Biosciences, Inc. (PLSE)

Over the past six months, Pulse Biosciences reported Q3, Q2 and Q1 2025 earnings, announced FDA approval of its nPulse IDE, initiated a research collaboration for thyroid cancer treatment, and had management meetings with Oppenheimer. Maria Sainz was appointed to its Board of Directors. The share price as of January 8, 2026, was $14.72, representing a decline of 20.28% from January 10, 2025.

Information regarding the demand seasonality for Pulse Biosciences, Inc.'s products and services is not explicitly available. Stock seasonality data indicates that buying PLSE stock in January has the highest probability of a positive return, while October has the lowest probability.

Pulse Biosciences, Inc. is a bioelectric medicine company focused on health innovation using its proprietary Nano-Pulse Stimulation (NPS) technology. The company's core technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. Its major products and platforms include the CellFX® System, CellFX nsPFA Percutaneous Electrode system, CellFX nsPFA Cardiac Clamp and CellFX nsPFA 360° Cardiac Catheter, and CellFX Consol.

Pulse Biosciences, Inc. is headquartered in Miami, Florida, United States. The company was founded in 2014 and was previously headquartered in Hayward, CA.

Pulse Biosciences has maintained a positive brand reputation due to its innovative technology and strategic advancements in nanosecond pulse field ablation technology. Recent positive events include FDA approval for its nPulse IDE and the initiation of research collaborations for thyroid cancer treatment.

Insiders own 81.64% of the company's shares, with Robert W. Duggan being the largest individual shareholder. Retail investors hold 9.73% of the shares. Institutional shareholders own 8.63% of the company's stock, with BlackRock, Inc. and Vanguard Group Inc among the largest institutional owners.